[go: up one dir, main page]

UY26530A1 - Composición. - Google Patents

Composición.

Info

Publication number
UY26530A1
UY26530A1 UY26530A UY26530A UY26530A1 UY 26530 A1 UY26530 A1 UY 26530A1 UY 26530 A UY26530 A UY 26530A UY 26530 A UY26530 A UY 26530A UY 26530 A1 UY26530 A1 UY 26530A1
Authority
UY
Uruguay
Prior art keywords
compound
hydrocarbyl
group
composition
ring
Prior art date
Application number
UY26530A
Other languages
English (en)
Inventor
Barry Victor Lloyd Potter
Michael John Reed
Walter Elger
Gudrun Roddersen
Heinrich-Thomas Proske
Original Assignee
Schering Ag
Sterix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0000792A external-priority patent/GB0000792D0/en
Priority claimed from GB0002115A external-priority patent/GB0002115D0/en
Application filed by Schering Ag, Sterix Ltd filed Critical Schering Ag
Publication of UY26530A1 publication Critical patent/UY26530A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Confectionery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

Se presenta una composición farmacéutica que comprende (i) un compuesto de la fórmula (I) en la cual: X es un anillo de hidrocarbilo con por lo menos 4 átomos en el anillo; es un grupo hidrocarbilo; Rs es grupo sulfamato; (ii) optativamente mezclado cib un vehículo, diluyente, excipiente o adyuvante farmacéuticamente aceptable, donde el compuesto está presente en una cantidad que produce una dosis de no más de 200 ag/día.
UY26530A 2000-01-14 2001-01-12 Composición. UY26530A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0000792A GB0000792D0 (en) 2000-01-14 2000-01-14 Composition
GB0002115A GB0002115D0 (en) 2000-01-28 2000-01-28 Composition
US21873000P 2000-07-17 2000-07-17

Publications (1)

Publication Number Publication Date
UY26530A1 true UY26530A1 (es) 2001-07-31

Family

ID=27255470

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26530A UY26530A1 (es) 2000-01-14 2001-01-12 Composición.

Country Status (26)

Country Link
EP (1) EP1248626B1 (es)
JP (1) JP2003519658A (es)
KR (1) KR20020087930A (es)
CN (1) CN1404394A (es)
AR (1) AR028196A1 (es)
AT (1) ATE332140T1 (es)
AU (1) AU2533101A (es)
BG (1) BG106914A (es)
BR (1) BR0107630A (es)
CA (1) CA2396098A1 (es)
CO (1) CO5280199A1 (es)
CZ (1) CZ20022282A3 (es)
DE (1) DE60121293T2 (es)
EE (1) EE200200391A (es)
ES (1) ES2267707T3 (es)
HR (1) HRP20020665A2 (es)
HU (1) HUP0300887A2 (es)
IL (1) IL150471A0 (es)
MX (1) MXPA01000464A (es)
NO (1) NO20023392L (es)
PE (1) PE20011121A1 (es)
PL (1) PL357020A1 (es)
SK (1) SK10022002A3 (es)
TR (1) TR200100070A2 (es)
UY (1) UY26530A1 (es)
WO (1) WO2001051055A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) * 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
GB0025788D0 (en) * 2000-10-20 2000-12-06 Sterix Ltd Use
EP1358882A1 (en) * 2002-04-30 2003-11-05 Schering Aktiengesellschaft Use of estriol sulfamate prodrugs for the treatment of autoimmune diseases
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
KR200449618Y1 (ko) * 2008-01-16 2010-07-23 주식회사 코비스 스포츠 그린보수기
GB201302368D0 (en) * 2013-02-11 2013-03-27 Univ Bath Compound
CN110809473A (zh) * 2017-06-01 2020-02-18 延世大学校产学协力团 用于预防或治疗骨相关疾病的药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen

Also Published As

Publication number Publication date
DE60121293D1 (de) 2006-08-17
CZ20022282A3 (cs) 2002-11-13
JP2003519658A (ja) 2003-06-24
CN1404394A (zh) 2003-03-19
TR200100070A3 (tr) 2001-08-21
BG106914A (en) 2003-01-31
ES2267707T3 (es) 2007-03-16
EP1248626A2 (en) 2002-10-16
WO2001051055A2 (en) 2001-07-19
WO2001051055A3 (en) 2002-03-21
IL150471A0 (en) 2002-12-01
EP1248626B1 (en) 2006-07-05
TR200100070A2 (tr) 2001-08-21
PL357020A1 (en) 2004-07-12
NO20023392L (no) 2002-09-16
AR028196A1 (es) 2003-04-30
HRP20020665A2 (en) 2004-12-31
KR20020087930A (ko) 2002-11-23
HUP0300887A2 (hu) 2003-07-28
AU2533101A (en) 2001-07-24
EE200200391A (et) 2003-12-15
ATE332140T1 (de) 2006-07-15
BR0107630A (pt) 2002-10-08
CO5280199A1 (es) 2003-05-30
SK10022002A3 (sk) 2002-12-03
DE60121293T2 (de) 2007-06-28
PE20011121A1 (es) 2001-11-05
NO20023392D0 (no) 2002-07-12
MXPA01000464A (es) 2003-07-21
CA2396098A1 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
PT102548A (pt) Formulacao farmaceutica para administracao por injeccao do composto 7alfa-¬9-(4,4,5,5,5-pentafluoropentilsulfinil)-nonil| estra-1,3,5(10)-trieno-3,17beta-diol (fulvestrant)
BR0015188A (pt) Composições farmacêuticas
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
ITRM920155A0 (it) Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil-1h-indol-5-metansolfonammide, e relativo procedimento di preparazione e trattamento con essa di mammiferi.
AR033859A1 (es) Inhibidores de la metaloproteinasa de la matriz
LU90366I2 (fr) Nasonex
MX9204625A (es) Composicion farmaceutica para el tratamiento de una especie de mamifero, que sufre de deficiencia cardiaca congestiva.
DE60019693D1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
ECSP045104A (es) Ligandos de los receptores de los cannabinoides
CO5280073A1 (es) Composiciones
GT199900154A (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
EA200400455A1 (ru) Способ приготовления быстрорастворимой дозировочной формы
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
BR0208017A (pt) Combinação compreendendo combretastatina e agentes anticâncer
AR027360A1 (es) Composicion farmaceutica
UY26530A1 (es) Composición.
ES2181366T3 (es) Derivados de piperidina que tienen efectos sobre sistemas relacionados con serotonina.
AR030379A1 (es) Combinaciones
BR9915692A (pt) Monohidrato de bromidrato de eletriptano
ES2173556T3 (es) Nuevos compuestos heterociclicos, su procedimiento de preparacion y los compuestos farmaceuticos que los contienen.
CO4940457A1 (es) Composiciones farmaceuticas que comprenden sensibilizadores a insulina para tratamiento de la diabetes
DE60234024D1 (de) Neue retinoidderivate und eine pharmazeutische anti-krebs-zusammensetzung, die diese verbindungen enthält
ES2194412T3 (es) Uso de derivados de hidantoina para la preparacion de un medicamento para el tratamiento de vasculitis resistente al tratamiento.
ES2170649B1 (es) Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.
TR200002293T2 (tr) Farmasötik bileşimler.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20120814